Endometriosis pain relief: letrozole takes on danazol in new study
NCT ID NCT07183787
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested two drugs, letrozole and danazol, to see which better reduces pelvic pain in women with endometriosis. Sixty women aged 18-45 with moderate to severe pain took one of the two drugs daily for 12 weeks. The main goal was to measure changes in pain scores, with the hope of finding a more effective or better-tolerated treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letrozole (2.5 mg daily) and danazol (200 mg twice daily), both taken orally for 12 weeks.
What this could lead to
If letrozole works as well as or better than danazol, it could offer a new, possibly better-tolerated option for managing endometriosis pain.
What could go wrong
This is a small, phase 2 study with only 60 participants, so results may not apply to everyone. Both drugs have side effects, and the study doesn't show long-term safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sharif Medical and Dental College
Lahore, Punjab Province, 54700, Pakistan